Biostar Pharmaceuticals, Inc.
BSPM
BSPM was delisted on the 18th of September, 2018.
7 hedge funds and large institutions have $330K invested in Biostar Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
31% more capital invested
Capital invested by funds: $251K → $330K (+$79K)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
13% less funds holding
Funds holding: 8 → 7 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$145K |
| 2 |
Morgan Stanley
New York
|
+$91.5K |
| 3 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
+$30.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$64K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$41K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$13.9K |
| 4 |
Barclays
London,
United Kingdom
|
-$1.19K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
JP Morgan Chase
New York
| $124K | +$145K | +42,477 | New |
|
|
AIM
2
Acrospire Investment Management
Chicago,
Illinois
| $94K | +$30.9K | +9,020 | +39% |
|
|
3
Morgan Stanley
New York
| $92K | +$91.5K | +26,747 | +575% |
|
4
Acadian Asset Management
Boston,
Massachusetts
| $12K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $7K | -$13.9K | -4,072 | -63% |
|
|
6
Barclays
London,
United Kingdom
| $1K | -$1.19K | -347 | -42% |
|
|
VKH
7
Virtu KCG Holdings
New York
| – | -$64K | -17,163 | Closed |
|
|
CS
8
Credit Suisse
Zurich,
Switzerland
| – | -$41K | -11,023 | Closed |
|
BSPM Hedge Fund Activity: Q4 2016 in Review
7 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Biostar Pharmaceuticals, Inc. (BSPM) for Q4 2016, worth a combined $330K — up 31% from $251K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BSPM and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.
The largest buyer was JP Morgan Chase, opening a new position worth an estimated $145K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $64K sold.
- 7 institutional investors held Biostar Pharmaceuticals, Inc. (BSPM) as of Q4 2016, down from 8 in Q3 2016.
- Funds reported $330K of Biostar Pharmaceuticals, Inc. stock for Q4 2016, up 31% quarter-over-quarter.
- 1 fund opened new Biostar Pharmaceuticals, Inc. positions in Q4 2016 and 2 closed out, a net change of -1 holder.
- The largest Biostar Pharmaceuticals, Inc. buyer in Q4 2016 was JP Morgan Chase, an estimated $145K added.
- The largest Biostar Pharmaceuticals, Inc. seller in Q4 2016 was Virtu KCG Holdings, an estimated $64K sold.
Based on aggregated 13F filings for Q4 2016.